Article
A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor.
International journal of hematology - 1 Apr 2021
Hara Ryujiro, Kawada Hiroshi, Kikuti Yara Yukie, Kikkawa Eri, Harada Kaito, Aoyama Yasuyuki, Ogiya Daisuke, Toyosaki Masako, Suzuki Rikio, Machida Sinichiro, Ohmachi Ken, Onizuka Makoto, Ogawa Yoshiaki, Masuda Ryota, Iwazaki Masayuki, Nakamura Naoya, Ando Kiyoshi
Abstract excerpt
The Janus kinase/signal transducers and activators of transcription signaling pathway induces programmed death ligand-1 (PD-L1) expression. JAK2 mutation at position 617 (JAK2V617) is a frequent driver of myeloproliferative neoplasms (MPN) through PD-L1 expression. Although PD-1 inhibitors should be effective against MPN with JAK2V617F mutation, this has not yet been reported in humans. Thus, we assessed the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.